Phil Hagerman

Diplomat Pharmacy: A multifaceted company

Diplomat Pharmacy: A multifaceted company

Describing itself as the nation’s largest independent specialty pharmacy, Diplomat Pharmacy Inc. serves patients and physicians in all 50 states and offers medication management programs for complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. The specialty pharmacy provider has made the most of

Diplomat steps to the fore in specialty Rx

Diplomat steps to the fore in specialty Rx

FLINT, Mich. — Diplomat Pharmacy Inc. is a growing company in a quickly growing industry. The specialty pharmacy provider has made the most of its independence, says chairman and chief executive officer Phil Hagerman, and continues to do so after last year’s initial public offering. Even though Diplomat has become publicly traded, “we absolutely still

Diplomat buys specialty pharmacy

FLINT, Mich. — Diplomat Pharmacy Inc. has acquired Burman’s Specialty Pharmacy in an $82.8 million deal. Burman’s, based in Pennsylvania, is a provider of individualized patient care with a primary focus on hepatitis C. “Burman’s shares our strong commitment to patient care,” said Diplomat chairman and chief executive officer Phil Hagerman. “We acquired Burman’s to

Diplomat acquires Burman’s Specialty Pharmacy

Diplomat acquires Burman’s Specialty Pharmacy

FLINT, Mich. — Diplomat Pharmacy Inc. has purchased Burman’s Specialty Pharmacy in a deal valued at more than $82 million. Diplomat said Friday that Burman’s, located in the greater Philadelphia area, is a provider of individualized patient care with a primary focus on hepatitis C. For the 12 months ended May 31, Burman’s generated about

Diplomat bulks up in infusion services

FLINT, Mich. — Diplomat Pharmacy, which posted strong financial results for fiscal 2014, is acquiring BioRx LLC, a specialized pharmacy and infusion services company. Based in Cincinnati, BioRx provides treatments for patients with ultra-orphan and rare, chronic diseases. Terms of the agreement call for Diplomat to buy BioRx for $210 million in cash and $105